Anchiano_high resolution.jpg
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
March 15, 2021 17:54 ET | Anchiano Therapeutics
Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be...
Anchiano_high resolution.jpg
Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
December 15, 2020 09:00 ET | Anchiano Therapeutics
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE...
Anchiano_high resolution.jpg
Anchiano Appoints Stan Polovets as Chairman of the Board
May 26, 2020 08:00 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of...
Anchiano_high resolution.jpg
Anchiano Therapeutics Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of new...
Anchiano_high resolution.jpg
Anchiano Appoints Steve DiPalma as Chief Financial Officer
May 05, 2020 18:13 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr....
Anchiano_high resolution.jpg
Anchiano to Hold Virtual Annual Meeting of Shareholders
April 17, 2020 16:01 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders...
Anchiano_high resolution.jpg
Anchiano Therapeutics Reports Year-End 2019 Financial Results
March 18, 2020 08:00 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to...
Anchiano_high resolution.jpg
Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders
January 17, 2020 16:05 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s...
Anchiano_high resolution.jpg
Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 15, 2019 08:30 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to...
Anchiano_high resolution.jpg
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program
November 15, 2019 08:30 ET | Anchiano Therapeutics
CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a biopharmaceutical company focused on discovery and development of...